Akademik Veri Yönetim Sistemi
Transfusion Clinique et Biologique, cilt.26, sa.1, ss.32-37, 2019 (SCI-Expanded)
Objectives: Chronic graft versus host disease (GVHD) is one of the major obstacles to achieve success in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Extracorporeal photochemotherapy (ECP) has been demonstrated to be an effective modality for the treatment of GVHD in previous studies but they vary in terms of initiation and duration. Our aim is to demonstrate the characteristics of our patients who received ECP for chronic GVHD to clarify the best treatment scheme. Material and methods: In this study, we retrospectively evaluated 34 patients with steroid refractory chronic GVHD (n = 34) who were treated with ECP between 2001 and 2015. The initiation of ECP was determined according to patient status and the physician's preference. Results: ECP was initiated early (≤ 3 months) as the preferred second-line treatment after failure of methylprednisolone treatment in 12 patients (35%), 22 steroid refractory patients (65%) received ECP later. In all cohorts, 10 (29%) and 14 (41%) of 34 patients achieved complete response (CR) and partial response (PR), respectively, with an overall response rate (ORR) of 70. Early initiation of ECP after chronic GVHD diagnosis (≤ 3 months vs more than 3 months) was associated with increased rates of response (92% vs 59%, P = 0.046) in which the severity of diseases were similar. Patients with skin involvement in early treatment group had statistically better response. Mild side effects were detected in only 6 patients (16%). Conclusion: ECP is a safe treatment modality and particularly effective when initiated soon after steroid failure in chronic GVHD.